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Ras proteins signal through direct interaction
with a number of effector enzymes, including
type I phosphoinositide (PI) 3-kinases. Although
the ability of Ras to control PI 3-kinase has been
well established in manipulated cell culture
models, evidence for a role of the interaction of
endogenous Ras with PI 3-kinase in normal
andmalignant cell growth in vivo has been lack-
ing.Herewegeneratemicewithmutations in the
Pi3kca gene encoding the catalytic p110a iso-
form that block its interaction with Ras. Cells
from these mice show proliferative defects and
selective disruption of signaling from growth
factors to PI 3-kinase. The mice display defec-
tive development of the lymphatic vasculature,
resulting in perinatal appearance of chylous as-
cites.Most importantly, they are highly resistant
to endogenous Ras oncogene-induced tumori-
genesis. The interaction of Ras with p110a is
thus required in vivo for certain normal growth
factor signaling and for Ras-driven tumor for-
mation.
INTRODUCTION
Activating point mutations in the genes encoding the Ras
subfamily of small GTP-binding proteins contribute to the
formation of a large proportion of human tumors. Analysis
of over 40,000 human tumor samples indicates an activat-
ing mutation rate of 22%, 8.2%, and 3.7% for KRAS,
NRAS, and HRAS, respectively (Catalogue Of Somatic
Mutations In Cancer, http://www.sanger.ac.uk/genetics/
CGP/cosmic/). The signaling pathways by which activated
Ras protein controls cell growth and contributes to malig-
nant transformation are therefore of considerable continu-ing interest. Several direct Ras effector enzyme families
have been characterized, the best studied of which are
Raf kinases, type I phosphoinositide (PI) 3-kinases, Ral-
guanine nucleotide exchange factors (Ral-GEFs), the Rac
exchange factor Tiam1, and phospholipase C 3 (Down-
ward, 2003). Of these, the genes encoding both B-Raf
and the p110a PI 3-kinase catalytic subunit have been
found to be frequently activated by somatic mutation in
human cancer (Weir et al., 2004), with overall mutation
frequencies around 10%–15% for each. PI 3-kinase activ-
ity is further implicated in carcinogenesis by the frequent
inactivation of the tumor suppressor gene PTEN, which
encodes the phosphatase that reverses the incorporation
of phosphate at the 30 position of the inositol ring (Cully
et al., 2006). However, genetic analyses of Ras signaling
in development of worms and flies has provided only
very limited evidence for a significant role for Ras effector
pathways other than Raf (Prober and Edgar, 2002).
In recent years, intense efforts have been made to de-
termine the relative importance of the different effector
pathways in the process of Ras-induced tumor formation.
For the most part, this has involved the exogenous ex-
pression in cultured cells of activated forms of the effector
proteins or of partial loss-of-function mutant Ras proteins
that have selective ability to interact with one effector
compared to another (Repasky et al., 2004). These exper-
iments have revealed varying effector dependencies of
Ras-induced transformation in different cell types and
species. However, the physiological significance of these
studies may be limited by the difficulty of using exoge-
nously expressed, artificially activated constructs in cul-
tured cells to mimic the amplitude and duration of Ras
effector activation in naturally occurring human tumors.
Another line of investigation has been to study chemical
carcinogenesis using dimethylbenzanthracene (DMBA),
which mutationally activates the endogenous Hras gene,
and phorbol ester to induce skin tumors in mice (Quinta-
nilla et al., 1986). When applied to mice in which genes
for key Ras effectors have been deleted, it has been foundCell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc. 957
that the presence of each of Tiam1, PLC3, and Ral-GDS is
required for skin tumor formation (Bai et al., 2004; Gonza-
lez-Garcia et al., 2005; Malliri et al., 2002). This implicates
these effectors in Ras-induced tumorigenesis although
does not formally prove that Ras acts through them, or
whether the tumor-suppressive effects of deletion of these
effectors are specific to Ras, rather than other oncogene,
induced carcinogenesis. Unfortunately it has not been
possible to undertake a similar analysis for the other major
Ras effectors due to the early lethality of mice deleted for
the Raf-1, B-Raf, p110a, and p110b genes (Vanhaese-
broeck et al., 2005; Wellbrock et al., 2004).
While the importance of endogenous PI 3-knase and
other non-Raf effectors in Ras-driven tumorigenesis re-
mains the subject of debate, it is even less clear how im-
portant these pathways are for normal growth factor
signaling in a physiological context. Overexpression of
a dominant-negative Asn17 Ras mutant partly inhibits in-
duction of PIP3 by epidermal and nerve growth factor in
cultured PC12 cells (Rodriguez-Viciana et al., 1994) and
by fibroblast growth factor in SKF5 cells (van Weering
et al., 1998). However, the specificity of this inhibitor of
Ras activity is uncertain. Little has been done to address
this issue in a whole animal context.
In this report we set out to study the importance of the
interaction of endogenous PI 3-kinase p110a with endog-
enous Ras in development and tumorigenesis in mice. An-
imals were made with point mutations knocked into the
Pi3kca gene that prevented interaction with activated
Ras. These mice show defects in lymphatic development
and are highly resistant to endogenous Ras oncogene-
induced tumorigenesis. The interaction of Ras with p110a
thus represents an important physiological component
of both normal and malignant Ras signaling.
RESULTS
Generation of Mice Bearing Mutations in PI 3-Kinase
p110a that Block Interaction with Ras
In order to investigate the role played by the interaction of
PI 3-kinase p110a with Ras in mammalian development
and tumorigenesis, we set out to generate mice in which
the interaction was disrupted by the introduction of point
mutations into the endogenous p110a gene. A previous
study of the structure of active Ras bound to a different
type I PI 3-kinase isoform, p110g, had identified four crit-
ical amino acids that are absolutely required for this inter-
action (Pacold et al., 2000). Although the degree of homol-
ogy between different type I PI 3-kinase isoforms is not
extremely high in the Ras-binding domain (RBD) (Vanhae-
sebroeck and Waterfield, 1999), two of the four amino
acids characterized as critical to the interaction of Ras
with p110g were conserved in human, cow, mouse, and
fly p110a (threonine 208 and lysine 227 in mammalian
pl10a, Figure 1A).
To determine whether mutation of these residues would
be sufficient to fully disrupt the interaction of Ras with
p110a, we changed threonine 208 to aspartic acid and ly-958 Cell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc.sine 227 to alanine, either separately or together. We
avoided reversing the charge of these sites as previous
studies had shown that mutation of lysine 227 to glutamic
acid had a significant stimulatory effect on the basal cata-
lytic activity of p110a, although substitution with neutral
alanine did not (Rodriguez-Viciana et al., 1996). We inves-
tigated whether GST-fusion proteins of the RBD of the mu-
tant forms of p110a were capable of binding to Ras. As
shown in Figure 1B, wild-type p110a very efficiently inter-
acted with both H- and K-Ras, but both the single and
double mutations on p110a abrogated its ability to bind.
Similar results were obtained in the reverse experiment,
where full-length wild-type and mutant forms of p110a
were mixed with GTP-bound GST-V12 H-Ras fusion pro-
tein (Figure 1C).
Based on the ability of the mutations T208D and K227A
to block the interaction of p110a with Ras, we set out to
introduce these two changes into the endogenous gene,
Pik3ca, encoding p110a in mice. Homologous recombina-
tion was used in ES cells to replace exon 3 with a version
containing the double mutation. These cells were used to
generate mice from which the neo selection cassette was
subsequently removed by breeding onto a strain express-
ing Cre in the germline (see schematic in Figure 1D).
Crosses of heterozygous mutant Pik3ca mice generated
live-born mice with wild-type, heterozygous mutant, and
homozygous mutant genotypes as determined by PCR
analysis (Figure 1D inset).
Disruption of the Interaction of p110a with Ras
Attenuates Growth Factor Signaling to the PI
3-Kinase Pathway and Cell Proliferation
Mouse embryonic fibroblasts (MEFs) were made from em-
bryonic day (E) 13.5 embryos from wild-type, heterozy-
gous mutant, and homozygous mutant genotypes. These
cells were used to determine the importance or otherwise
of the direct interaction of endogenous p110a with endog-
enous Ras for the ability of various growth factors to acti-
vate downstream signaling pathways, in particular ones
where Ras could be directly involved, such as Raf/MEK/
ERK and PI 3-kinase/Akt. Stimulation of wild-type MEFs
with EGF, FGF2, or PDGF led to the activation of both
the ERK and Akt pathways as determined by the appear-
ance of phosphorylated ERK and phosphorylated Akt,
as expected. However, in cells homozygous for the muta-
tion in the RBD of p110a, we found that Akt activation
in response to EGF was significantly reduced and FGF2
signaling to Akt was completely abrogated (Figure 2A).
In contrast, PDGF signaling was unaffected in mutant
cells as well as ERK signaling in response to EGF and
PDGF.
Analyzing a dose-response curve for suboptimal con-
centrations of PDGF revealed no difference in the level
of Akt or ERK activation between mutant and wild-type
cells but deficient signaling to Akt, but not ERK, through-
out the whole range of EGF concentrations (Figure 2B).
Since PI 3-kinase has been shown to be important in in-
sulin signaling and glucose homeostatsis (Foukas et al.,
Figure 1. Generation of Mice Bearing
Mutations in PI 3-Kinase p110a that
Block Interaction with Ras
(A) Schematic of the domain structure of p110a
and alignment of p110 isoforms from several
species. The red blocks indicate mutations
made to disrupt the interaction of p110a with
Ras. The alignment was carried out using
the clustal algorithm of Lasergene Navigator
(DNASTAR).
(B) Wild-type and mutant forms of the GST-
tagged Ras-binding domain (RBD) of p110a
were expressed in COS7 cells, along with the
activated V12 mutant form of H-Ras or K-Ras.
The cells were lysed and GST-p110 RBD was
recovered on glutathione agarose. Bound V12
Ras was detected with pan-Ras antibody.
(C) Untagged p110a and p85a were transiently
overexpressed in COS7 cells. Cell extracts
were made and added to GTP-loaded V12 H-
Ras GST fusion protein bound to glutathione
agarose. The Ras beads were washed and
bound p110a detected by western blotting
with p110a antibodies.
(D) Schematic representation of the strategy for
introduction of the T208D and K227A muta-
tions into exon 3 of pik3ca, the gene encoding
p110a in mice. Arrows indicate the location of
genotyping primers. Inset: genotyping PCR of
samples after Cre-mediated excision of the
neomycin selection cassette. The upper band
represents the mutant allele (containing a resid-
ual 30 base pairs of the loxP site). The lower
band represents the wild-type allele.2006), we also looked at the insulin responsiveness of
wild-type and mutant MEFs but found little difference
(data not shown). To confirm that the differences seen in
Akt activation reflected alterations in PIP3 levels in the
cell, immunocytochemistry with a PIP3-specific monoclo-
nal antibody was used. As seen in Figure 2C, in response
to EGF, mutant MEFs showed highly reduced levels of
PIP3 compared to wild-type MEFs, while PDGF stimula-
tion was similar in the two genotypes.
To establish whether these differences arose due to al-
tered regulatory signaling to the mutant p110a or funda-
mental defects in its enzymatic activity, we characterized
the protein in further detail. As shown in Figure S1A avail-
able with this article online, the in vitro lipid kinase activity
of immunoprecipitated mutant p110a is indistinguishable
from that of the wild-type p110a. Also the amount of p85
coimmunoprecipating with mutant p110a was similar to
that with wild-type p110a, thereby suggesting that the
binding affinity of p110a for p85 is not affected by the
RBD mutations (Figure S1B). In addition, the binding of
p85 to tyrosine-phosphorylated proteins following growthfactor stimulation also remains unaltered in cells bearing
the p110a RBD mutations (Figure S1C). Furthermore, the
level of expression of p110a in MEFs was the same for
each genotype, as were the expression levels of p110b
and p85 (Figure S1D). p110d and p110g expression was
not detectable by immunblot in these cells (data not
shown).
It thus appears likely that the mutations in the RBD do
not interfere with the basic enzymatic activity of p110a,
its coupling to the p85 regulatory subunit, or expression
of PI 3-kinase components, suggesting that the biological
effects of these mutations are indeed reflecting altered
coupling to Ras. To further confirm this, dominant-nega-
tive mutant Ras (N17) was cotransfected with epitope-
tagged Akt into wild-type MEFs, which were subsequently
stimulated with growth factors. Tagged Akt was immuno-
precipitated and its kinase activity assayed in vitro. As
shown in Figure S1E, the ability of EGF and FGF2 to acti-
vate Akt was completely abolished by dominant-negative
Ras in this assay, while that of PDGF was much less
affected. Similar observations have been previouslyCell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc. 959
Figure 2. Disruption of the Interaction of
p110a with Ras Attenuates Growth Fac-
tor Signaling to the PI 3-Kinase Pathway
and Cell Proliferation
(A) Serum-starved wild-type and p110a mutant
MEFs were stimulated with EGF (50 ng/ml),
FGF2 (20 ng/ml), or PDGF (20 ng/ml) for 10
min prior to lysis of cells and analysis of the
phosphorylation state of ERK and Akt by West-
ern blotting.
(B) Serum-starved wild-type and p110a mutant
MEFs were stimulated with EGF or PDGF at the
indicated concentrations (ng/ml) for 10 min
prior to lysis of cells and analysis of the phos-
phorylation state of ERK and Akt by Western
blotting.
(C) Serum-starved wild-type and p110a mutant
MEFs were stimulated with EGF (50 ng/ml),
FGF2 (20 ng/ml), or PDGF (20 ng/ml) for 10 min
prior to immunocytochemistry staining for PIP3.
(D) To quantify effects of p110a mutation on
cell-cycle progression, wild-type, mutant, and
heterozygous MEFs were pulse-labeled with
BrdU in serum-containing medium. Cells were
analyzed by FACS for staining with antibody
to BrdU and for total DNA content with propi-
dium iodide. The proportions of cells in G1, S,
and G2/M phases of the cell cycle are shown
graphically.made in other cell systems (Rodriguez-Viciana et al., 1994;
van Weering et al., 1998).
The decreased responsiveness of the PI 3-kinase path-
way, a key regulator of cellular proliferation, survival, and
metabolism, to certain growth factors raised the issue of
whether there was a defect in the growth of cells in which
the Ras-p110a interaction was disrupted. To quantify the
proportion of actively dividing cells in the different popula-
tions, we pulse-labeled MEFs growing in serum containing
medium with BrdU. The proportion of homozygous mutant
cells in S phase was considerably reduced compared to
wild-type and heterozygous cells, and a larger proportion
of the mutant cells had accumulated in the G1 and G2
phases of the cell cycle (Figure 2D). There was little differ-
ence, however, in the number of apoptotic cells or in cell
size in the different MEF populations (data not shown).
Activation of the PI 3-Kinase Pathway by Oncogenic
Mutant Ras Requires Direct p110a-Ras Interaction
The ability of expression of oncogenic mutant Ras to in-
duce activation of PI 3-kinase is well established (Rodri-
guez-Viciana et al., 1994). However, the possibility existed
that this effect was indirect, driven by interaction of Ras
with effectors other than PI 3-kinase, possibly through960 Cell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc.the stimulation of transcriptional changes leading to auto-
crine growth factor production. To address whether the di-
rect interaction of Ras with p110a is needed in order for
oncogenic mutant Ras to stimulate the PI 3-kinase path-
way, we made use of a posttranslationally inducible acti-
vated form of Ras, ER:V12 H-Ras (Dajee et al., 2002). In
this construct, the hormone-binding domain of the estro-
gen receptor is fused to the amino terminus of an activated
mutant of H-Ras. On addition of the ligand 4-hyroxyta-
moxifen (4HT), steric hindrance of Ras is relieved leading
to its ability to interact with effectors. In serum-starved
wild-type immortalized MEFs stably expressing ER:V12
H-Ras, addition of 4HT rapidly leads to activation of both
ERK and Akt, with phosphorylation of these targets visible
within 10 min (Figure 3). In contrast, MEFs expressing the
RBD mutant p110a fail to activate Akt significantly even af-
ter 24 hr induction with 4HT, although ERK activation is
normal. These data therefore confirm that direct interac-
tion of Ras with PI 3-kinase is crucial for Akt activation.
Mice Deficient in the Interaction of p110a with Ras
Have Defective Lymphatic Development
When animals heterozygous for the p110amutations were
interbred, we observed that the number of homozygous
mutant animals obtained on genotyping at two weeks of
age (2%) was significantly below that expected (Table
1). Analysis of E18.5 embryos of similar litters demon-
strated a ratio of homozygous mutant animals that was
close to Mendelian (19%), while the ratio for one-day-old
pups was 9%, suggesting that some mutant animals
were being lost around the time of birth. The number of
pups counted shortly after birth was higher than the num-
ber that remained after 14 days because a number of ap-
parently sick animals had to be culled in the first few days
after birth, in accordance with local animal welfare regula-
tions. Closer examination of pups just after birth revealed
that most mutant animals exhibited a milky appearance of
Figure 3. Activation of the PI 3-Kinase Pathway byOncogenic
Mutant Ras Requires Direct p110a-Ras Interaction
Wild-type and mutant MEFs were immortalized with SV40 T antigen
and then infected with a retroviral construct, ER:V12 H-Ras, express-
ing inducibly activatable Ras. Stable drug-selected populations of
cells were assessed for the ability of 4-hyroxytamoxifen (4HT) to in-
duce phosphorylation of Akt and ERK. Cells were serum starved for
16 hr followed by induction with 100 nM 4HT for the indicated times.
Cells were then harvested and probed with the indicated antibodies
by Western blotting.the peritoneum (Figure 4A). This is a sign of chylous asci-
tes, a condition caused by the leakage of lymphatic fluid
into the peritoneal cavity, where it can cause an inflamma-
tory response that can lead to death. In newborn animals,
this is usually associated with developmental malforma-
tion of the intestinal lymphatic system (Press et al., 1982).
To determine the cause of the suspected chylous asci-
tes, sections of bowel from newborn pups were examined
for any abnormality in their tissue architecture. The jeju-
num demonstrated an edemal accumulation of fluid in
the submucosal layer of the intestinal wall (Figure 4B). Be-
cause this region of the submucosa contains the lym-
phatic network collecting chyle from the intestinal lacteals,
we suspected that the p110a mutant mice had an abnor-
mally developed lymphatic system in this section of the in-
testine. Closer examination of the lymphatic vasculature
system in the mutant mice revealed deficient branching
and development of the network. Staining of E18.5 em-
bryos for the receptor tyrosine kinase VEGFR-3, the re-
ceptor for VEGF-C and VEGF-D, which is expressed in
the lymphatic endothelium (Dumont et al., 1998, Kaipai-
nen et al., 1995), showed that although major lymph ves-
sels in the thoracic cavity, such as the thoracic duct,
were present in the mutants, the finer vessels of the lym-
phatic network, such as the intercostal vessels, were
completely absent (Figure 4C). Similar analysis of the
skin and diaphragm of E18.5 embryos showed highly re-
duced numbers of vessels and a much-reduced level of
network branching (Figure 4D). Staining for another
marker of the lymphatic network, the homeodomain tran-
scription factor PROX-1, confirmed the lack of a fully de-
veloped lymphatic network in the mesenterium of p110a
mutant mice (Figure 4E).
A relatively small proportion of the p110a mutant mice
survived into adulthood. These mice appeared to be
healthy, and any signs of chylous ascites disappeared.
Analysis of the lymphatic vasculature in these surviving
adult mice revealed it to be normal (data not shown), sug-
gesting either that the lymphatic system recovers from its
earlier retarded development or that the severity of the de-
velopmental defect is variable and in a minority of mutant
mice the lymphatics develop normally. However, the mu-
tant mice that survived to adulthood exhibited a reduced
body weight that remained below wild-type levels at all
stages of growth (Figure S2).Table 1. Disruption of the Interaction of p110a with Ras Leads to Reduced Numbers of Surviving Mice
Parental cross #1: het 3 het #2: het 3 het #3: het 3 het
Litter age at genotyping 14 days after birth 1 day after birth Embryonic day 18.5
Wild-type 124 30 23
Heterozygous mutant 283 77 33
Homozygous mutant 8 10 13
% homozygous mutant obtained 2% 9% 19%
Table showing numbers of animals produced from heterozygote/heterozygote crosses for each genotype when analyzed at differ-
ent ages. Each group represents an independent set of animals.Cell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc. 961
Figure 4. Mice Deficient in the Interac-
tion of p110a with Ras Have Defective
Lymphatic Development
(A) p110a mutant mice exhibit chylous ascites:
picture of mutant as compared to wild-type
new-born mouse pups demonstrating the ac-
cumulation of chyle in the abdominal cavity.
(B) Histological analysis of the intestine of new-
born mice reveals an abnormality in the submu-
cosal layer of the jejunum in p110a mutants.
(C) p110a mutant mice exhibit deficient devel-
opment and branching of the lymphatic sys-
tem. Whole-mount examination with VEGFR3
staining of mutant E18 embryos demonstrates
the presence of the thoracic duct (arrowhead)
but shows the lack of an extensive branching
network in the intercostal region of the thorax
(arrows).
(D) Similar examination of the diaphragm and
the skin of p110a mutant E18 embryos shows
complete absence of the lymphatic system in
the diaphragm and deficient branching of the
lymphatic vessels in the skin.
(E) Staining of the mesenteric lymphatic net-
work with PROX-1 antibody indicates reduced
numbers of lymphatic endothelial cells in mu-
tant animals.Disruption of the Interaction of p110a with Ras
Inhibits In Vitro Transformation of Fibroblasts
To assess the requirement of the interaction of 110a with
Ras for the ability of Ras and other oncogenes to trans-
form murine fibroblasts in vitro, MEFs from wild-type, het-
erozygous, and homozygous mutant p110a animals were
immortalized by expression of SV40 large T antigen, then
infected with retroviral vectors expressing activated mu-
tant H-Ras, activated mutant EGF receptor L858R, or pol-
yoma virus middle T oncogene. These cell populations
were then tested for their degree of transformation by as-
sessing their ability to form colonies in soft agar (Fig-
ure 5A). As quantified in Figure 5B, wild-type MEFs
expressing activated H-Ras grew independently of an-
chorage whereas homozygous mutant MEFs completely
failed to show transformation by H-Ras. The heterozygous
cells showed somewhat reduced transformation effi-
ciency by H-Ras. All three genotype MEFs were found to
be expressing H-Ras at similar levels as determined by im-
munoblotting (data not shown). The ability of activated
EGF receptor to transform MEFs was also compromised
by homozygous mutation of the p110a RBD, but polyoma
middle T transformed all three genotypes equally well.
Since anchorage-independent growth is a hallmark of on-
cogenic transformation in vitro, these data support a direct962 Cell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc.cell-autonomous role for the Ras-PI 3-kinase interaction in
Ras-mediated tumorigenesis and also in transformation
by some other oncogenes known to act upstream of
Ras, such as EGF receptor. In addition to effects on trans-
formation by H-Ras, p110a RBD mutation also compro-
mised the ability of K-Ras to transform MEFs (Figure S3).
Disruption of the Interaction of p110a with Ras
Blocks Carcinogenesis Driven by K-Ras
In order to investigate whether the ability of endogenous
p110a to interact with endogenous Ras plays a role in car-
cinogenesis caused by oncogenic mutation of the K-Ras
gene in vivo, the p110a mutant mice were bred with K-
Ras LA2 mice. In this strain, an activating mutation has
been introduced into one allele of the K-Ras gene, but ex-
pression is silenced by a disrupting sequence. This is lost
by homologous recombination at very low frequency, re-
sulting in the expression of oncogenic K-Ras protein at en-
dogenous levels in a small number of cells in each tissue.
The mice develop lung adenocarcinomas at high fre-
quency, with most of the mice dying due to tumor burden
by 200 days of age (Johnson et al., 2001).
Mice that were homozygous for the Pi3kca mutation
and carried one copy of the K-Ras LA2 transgene showed
similar survival rates in the first few weeks of life to
equivalent mice lacking K-Ras mutation. These mice were
sacrificed at 4 months and the numbers of tumor nodules
visible on the lung surface were counted. The number of
tumors occurring in thePi3kcamutant mice was massively
reduced compared to those with wild-type PI 3-kinase.
While the K-Ras LA2 mice typically had forty or so macro-
scopic tumors on the surface of the lung, the Pi3kca mu-
tant mice had between zero and two visible tumors, and
these were much smaller (Figure 6A). One Pi3kca mutant
K-Ras LA2 mouse was aged to 6 months and found to
be still entirely free of macroscopically detectable lung tu-
mors (data not shown).
Histological analysis of the Pi3kca mutant mouse lung
tissue revealed that they did contain some foci of abnor-
mal cells that might represent premalignant lesions. How-
ever, these were very small compared to tumors found in
K-Ras LA2 animals on a wild-type background (Figure 6B).
In addition, we used immunohistochemistry with phos-
phospecific antibodies to study the activation state of
Figure 5. Disruption of the Interaction of p110a with Ras In-
hibits In Vitro Transformation of Fibroblasts
MEFs from wild-type, heterozygous, and homozygous mutant animals
were immortalized by expression of SV40 large T antigen. Immortal-
ized cells were then infected with activated mutant H-Ras V12, acti-
vated mutant EGF receptor L858R, or polyoma middle T. Selected sta-
ble populations of cells were tested for their ability to grow in an
anchorage-independent manner in soft agar.
(A) Representative images of macroscopic colonies formed after 3
weeks are shown.
(B) Quantification of the numbers of colonies formed. Error bars shown
are standard errors of the mean for triplicate samples.Akt in the tumors and premalignant lesions in the K-Ras
LA2 animals on the Pi3kca mutant and wild-type back-
grounds. As shown in Figure S4A, there is evidence that
Akt is activated in the Ras-induced tumors found in the
wild-type mice but not in the lesions found in the PI 3-
kinase mutant background.
Furthermore, the levels of cell proliferation, apoptosis,
and senescence were studied in the tumors and premalig-
nant lesions of these animals. As shown in Figure S4B,
TUNEL assays revealed low levels of apoptosis in Ras-
induced tumors found on a wild-type background, but
there were signs of significant levels of apoptosis occur-
ring in the small lesions found on the PI 3-kinase mutant
background. The proliferative rates in the lesions and
tumors in the two backgrounds were similar, as measured
by phospho-histone H3 staining for mitotic cells (Fig-
ure S4C), so it is likely that the difference in the sizes of
the tumors in the wild-type and the PI 3-kinase mutant
backgrounds is at least in part due to elevated rates of
cell death in the absence of direct Ras binding to p110a.
Another way of looking at the efficiency of Ras-induced
tumor formation is to use the two-stage skin carcino-
genesis protocol using initiation with the mutagen DMBA
(7,12-dimethylbenzanthracene), which causes activating
mutations in the murine H-ras gene, and promotion with
the phorbol ester TPA (12-O-tetradecanoylphorbol-13-
acetate). As shown in Figure S5, PI 3-kinase mutant
mice were much more resistant than wild-type mice to
the formation of skin tumors by this means. This experi-
ment was performed on a mouse background, C57BL/6,
that is relatively resistant to papilloma formation, so overall
tumor numbers formed are low, even for the wild-type
mice.
DISCUSSION
A Physiological Role for Ras in the Regulation
of PI 3-Kinase by Growth Factors
The creation of mice lacking the ability of their p110a PI 3-
kinase catalytic subunit to interact with activated Ras
provides an opportunity to definitively address the signifi-
cance of this interaction in growth factor signaling both in
vivo and in vitro. In cultured mouse embryo fibroblasts,
loss of p110a binding to Ras strongly reduces PI 3-kinase
activation by EGF and FGF-2, but not by PDGF. This dif-
ferential requirement for Ras may reflect the fact that the
activated receptor for PDGF directly binds the p85 regula-
tory subunit of PI 3-kinase at the plasma membrane
(Kazlauskas and Cooper, 1989), whereas the others do
not. EGF receptor is thought to direct PI 3-kinase activa-
tion more indirectly, either via Gab1 and Grb2 or via
ErbB3 (Mattoon et al., 2004; Soltoff et al., 1994). In the
case of FGF-2, its receptor phosphorylates the docking
protein FRS2, which in turn binds Grb2 and Gab1 (Ong
et al., 2001). Where PI 3-kinase is recruited to receptor
complexes indirectly, it is possible that smaller numbers
of p110 molecules are activated, perhaps making a costi-
mulatory role for Ras binding more essential. On the otherCell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc. 963
Figure 6. Disruption of the Interaction of
p110a with Ras Blocks Carcinogenesis
Driven by K-Ras
(A) Tumour nodules on the surface of the lungs
in K-Ras LA2 mice on wild-type andPi3kcamu-
tant backgrounds. Note the appearance of just
one tumor nodule (1 mm diameter) on the mu-
tant lung and several macroscopic nodules of
different sizes on the wild-type lung. The lower
panel shows quantitation of the tumors found in
three Pi3kca mutant and six wild-type K-Ras
LA2 mice at 120 days. Error bars shown are
standard errors of the mean for triplicate
samples.
(B) H&E staining of oncogenic K-Ras mouse
lungs. The arrows indicate small adenomatous
hyperproliferations seen in the lungs of Pi3kca
mutant mice. The large arrowhead indicates
a typical adenocarcinoma in a mouse with
wild-type Pi3kca.hand, other considerations may also be involved, as insu-
lin signaling to PI 3-kinase, which involves IRS family
adaptors, does not appear to be majorly dependent on
Ras interaction with p110a. Another possible explanation
might be the extent to which particular growth factor
receptors use different isoforms of p110. Deletion of
p110a in mouse embryo fibroblasts results in more com-
plete inhibition of EGF than PDGF signaling to Akt (Zhao
et al., 2006). It has been suggested that this might reflect
an ability of PDGF, but not EGF, receptor to regulate
p110b, which is also expressed in these cells.
Very recently, mice have been made where a similar set
of mutations has been introduced into a different isoform
of PI 3-kinase, p110g, whose expression is largely re-
stricted to hematopoietic cells. This resulted in loss of ac-964 Cell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc.cumulation of PIP3 in neutrophils in response to chemoat-
tractants (Suire et al., 2006). In addition, flies with a similar
mutation introduced into Dp110 show greatly reduced
egg-laying ability and are small in size (Orme et al.,
2006). This suggests that blocking Ras interaction with
p110 can attenuate PI 3-kinase regulation in other sys-
tems as well.
Interaction with Ras has been shown to allosterically
activate PI 3-kinase via a change in the structure of the
catalytic pocket (Pacold et al., 2000), in a manner that is
synergistic with binding of p85 to pYXXM peptides
(Rodriguez-Viciana et al., 1996). By itself, the interaction
of Ras with p110 is insufficient to drive membrane translo-
cation of PI 3-kinase, a necessity for its activation (Suire
et al., 2002), suggesting that the ability of oncogenic
mutant Ras by itself to drive PI 3-kinase activation may be
dependent on low-level signaling input from receptor tyro-
sine kinases, especially EGF receptor family members
that respond to autocrine ligands produced in response
to activation of the Raf/ERK branch of Ras downstream
pathways (Schulze et al., 2001).
The phenotype of mice homozygous for the p110a RBD
mutation suggests that in vivo there is also a requirement
for the Ras/PI 3-kinase interaction for some growth factors
to signal correctly. Most obviously, there is a partial failure
and delay of development of the lymphatic system, result-
ing in the accumulation of chylous ascites in newborn
pups. This developmental phenotype is similar to that of
VEGF-C+/ mice (Karkkainen et al., 2004) and also to
some extent angiopoietin 2 knockout mice (Gale et al.,
2002). The sprouting of the first lymphatic vessels from
embryonic veins appears to be highly dependent on
VEGF-C signaling, with homozygous deletion of VEGF-C
resulting in embryonic edema from E12.5, complete lack
of lymphatic vasculature, and death in utero. The similarity
of the phenotype of the VEGF-C heterozygotes and p110a
RBD mutant homozygotes could suggest that failure of
Ras to engage p110a directly might result in vivo in
a roughly 50% reduction in the ability of VEGF-C to signal
to a critical downstream effector system, such as PI 3-
kinase/Akt. It has been demonstrated that VEGF-C pro-
motes survival and proliferation of lymphatic endothelial
cells in vitro and induces Akt and ERK activation (Makinen
et al., 2001b). VEGF-C signals through two receptor tyro-
sine kinases, VEGFR2 and VEGFR3, of which VEGFR3 is
critical for its role in control of lymphatic development
(Joukov et al., 1996; Makinen et al., 2001a, 2001b).
VEGFR3 makes a good candidate for a receptor that
might require Ras to signal to PI 3-kinase as, like EGFR
and FGFRs, it lacks good p85-binding motifs and presum-
ably must engage the pathway indirectly. However, it is
also possible that signaling through other lymphangio-
genic growth factors and their receptors, such as angio-
poeitin 2 and Tie2, could also be defective in the p110a
RBD mutant mice.
It is striking that one of several defects suffered by mice
deleted for the Pik3r1 gene, which encodes the PI 3-
kinase regulatory subunits p85a, p55a, and p50a, is the
formation of chylous ascites (Fruman et al., 2000). These
mice have reduced levels of p110a protein and lipid kinase
activity but show much more widespread problems, in-
cluding extensive liver necrosis and hypoglycaemia, indi-
cating the relatively selective nature of the impact on PI 3-
kinase signaling of disrupting the Ras/PI 3-kinase link.
However, in the animals reported here, in addition to the
effects on lymphatic development, it is possible that other
growth factor signaling pathways may be defective that
are not essential under the husbandry conditions em-
ployed. Moreover, the decreased size of these animals
may reflect defects in systemic growth regulation, al-
though at present it cannot be ruled out that it is an indirect
manifestation of the perinatal lymphatic development
defect.The Importance of Ras Interaction with PI 3-Kinase
in Tumorigenesis
While the results discussed above clearly show that Ras
interaction with PI 3-kinase is needed for some normal
growth factor signaling, the ability of activated mutant
Ras to cause transformation in vitro and tumor formation
in vivo also requires PI 3-kinase p110a to have a functional
RBD. The striking effect of homozygous mutation of
p110a RBD on the ability of a sporadically activated single
D12 K-Ras allele expressed at endogenous levels to
cause lung tumor formation suggests that, at least in this
setting, oncogenic Ras is highly dependent on its ability
to stimulate PI 3-kinase directly in order to drive tumori-
genesis in vivo.
Hundreds of lung adenocarcinomas form in K-Ras LA2
mice by 4 months of age, resulting in death by 6 months
(Johnson et al., 2001). The rate of lung tumor formation
is cut by more than 95% by the introduction of point mu-
tations in p110a blocking its interaction with Ras. Nor-
mally, the adenocarcinomas in K-Ras LA2 mice show ev-
idence of Akt activation, suggesting that Ras is inducing
this effector pathway in the tumors. Very few tumors
form in the PI 3-kinase mutant animals, although they do
show significant areas similar to atypical adenomatous
hyperplasia (AAH), thought to be a premalignant condition
that may progress to adenocarcinoma (Nakahara et al.,
2001). The AAH-like lesions in the PI 3-kinase mutant
mice do not exhibit Akt activation. It appears likely that
these hyperplastic lesions fail to develop into tumors
due to defective Akt activation, resulting in increased rates
of apoptosis. In this manner the lung epithelial cells differ
from the embryonic fibroblasts derived from these mice,
where the major effect of the mutation of PI 3-kinase ap-
peared to be on cell proliferation rather than survival. We
have not been able to observe obvious signs of senes-
cence in the AAH lesions using b-galactosidase staining,
although this has been observed in a different K-Ras-
driven mouse lung cancer model (Collado et al., 2005).
The simplest explanation for the failure of tumors to de-
velop in the PI 3-kinase mutant mice is that lung epithelial
cells expressing activated Ras fail to activate Akt, which is
directly required for their proliferation and survival. Clones
of activated Ras-expressing epithelial cells thus fail to
grow beyond a limited size. However, it is also possible
that the defect is not entirely cell autonomous: the PI 3-
kinase mutant epithelial cells may be deficient in their in-
teraction with surrounding stroma. They could be unable
to induce angiogenesis, although the lesions may well be
too small to require new vasculature. It is also conceivable
that they have an altered interaction with the host immune
system. In each case these possible problems could be
caused either by defects in the activated Ras-expressing
epithelial cells themselves or in the surrounding host tis-
sues, which also carry the PI 3-kinase mutation, even
though they lack expression of activated Ras. The possi-
bility of defects in tumor neovascularization might be
raised by the deficiencies in the related lymphangiogene-
sis system in the PI 3-kinase mutants, although there is noCell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc. 965
indication that there is any developmental problem with
normal blood vessel formation in these mice. Defects in
lymphangiogenesis itself are very unlikely to account for
failure of primary tumors to develop, although the lym-
phatics are important for metastatic spread of established
tumors (Saharinen et al., 2004). In any case, the lymphatic
system is apparently normal in the lungs of the PI 3-kinase
mutant mice once they reach adulthood.
Study of the ability of exogenously introduced Ras to
transform immortalized fibroblasts fromnormaland PI 3-ki-
nase mutant mice in vitro suggests that there is at least
a major cell-autonomous component to the impact of PI
3-kinase RBD mutation on Ras-induced tumorigenesis.
This in vitro system also allows rapid study of the specificity
of the effect of this mutation on different oncogenic signal-
ing pathways. Like activated Ras, oncogenic mutant EGF
receptor requires Ras interaction with p110a to induce col-
ony formation in soft agar, but the ability of polyoma virus
middle T antigen to transform fibroblasts is not affected.
Polyoma middle T activates PI 3-kinase strongly via direct
binding to p85 via sites phosphorylated by c-Src (Whitman
et al., 1985), presumably without need for synergistic input
from Ras. We are also in the process of addressing the
specificity of the inhibitory effect of the p110a RBD muta-
tion on tumorigenesis in vivo for oncogenes other than Ras.
The results presented here prove that the direct interac-
tion of Ras with the catalytic subunit of type I PI 3-kinase is
important in both malignant and normal developmental
growth signaling. The strong reduction in Ras-induced
lung tumor formation when this binding is prevented sug-
gests that specific targeting of the interaction of Ras with
PI 3-kinase may have therapeutic value in the treatment of
tumors, such as lung, colon, and pancreatic carcinoma,
with high incidences of Ras mutation. In addition, since
adult mice lacking Ras binding to PI 3-kinase are appar-
ently healthy, drugs targeting this link might be expected
to be well tolerated.
EXPERIMENTAL PROCEDURES
Reagents
The murine p110a genomic clones (gm35 and gm45) were a kind gift
from Dr. Tom Roberts (Dana Farber Cancer Institute). Bovine p110a,
V12 H-Ras, V12 K-Ras, and Myc expression constructs were described
previously (Rodriguez-Viciana et al., 1997). EGF, PDGF-AB, and FGF2
were obtained from R&D systems. BrdU was purchased from Sigma.
The oncogenic K-Ras mouse strain (Kras-LA2) was from the MMHCC
mouse repository (NCI-Frederick). The ER:V12 H-Ras construct (Dajee
et al., 2002) was a kind gift from Dr. Paul Khavari (Stanford University).
Antibodies
The pan-ERK, phospho-ERK (E10) monoclonal, and phospho-Akt
(Ser473) antibodies were all purchased from Cell Signaling Technol-
ogy. The Pan-Ras (Ab-4) antibody was obtained from Calbiochem,
the p85 (06-195) antibody from Upstate, and the p110b (Sc-602) anti-
body from Santa Cruz. The antibody recognizing bovine p110a was
from Transduction Laboratories. The monoclonal hybridoma tubulin
(TAT-1), Akt, and GST antibodies were generated in-house. The
VEGFR-3 antibodies were from R&D Systems, the Cy3-conjugated
SMA antibody was from Sigma, and the PROX-1 antibody was
a kind gift from Dr. Tatiana Petrova. The mouse-specific p110a anti-966 Cell 129, 957–968, June 1, 2007 ª2007 Elsevier Inc.body was a kind gift from Antonio Biliancio and Bart Vanhaesebroeck
(Ludwig Institute for Cancer Research, University College London). HA
antibody monoclonal antibody 12CA5 was from Abgent, and in vitro ki-
nase assays on HA-Akt immunoprecipitates were performed as in
Alessi et al. (1996).
Proliferation Assays
Cells were pulsed with BrdU for 1 hr, prior to trypsinization and fixation
in ethanol. FACS analysis was performed on a FACScalibur (Becton
Dickson).
PIP3 Immunocytochemistry
Wild-type and mutant MEFs cultured on coverslips were serum-
starved overnight and stimulated with EGF (50 ng/ml), FGF2 (20 ng/
ml), or PDGF (20 ng/ml) for 10 min. Reactions were stopped by wash-
ing the cells with cold TBS. Cells on glass coverslips were fixed with
4% formaldehyde and then permeabilized with 0.5% Triton X-100 in
TBS. Immunocytochemistry was performed using a Histostain-Plus
Kit (Invitrogen), according to the manufacturer’s protocol. PIP3 levels
were detected with mouse anti-PIP3 monoclonal antibody (Z-G345;
Echelon) diluted at 1:50 overnight at 4C.
Whole-Mount Immunostaining
Tissues were fixed in 4% paraformaldehyde and used for whole-mount
immunofluorescence or immunoperoxidase staining. For immuno-
fluorescence, tissues were stained with goat anti-mouse VEGFR-3,
Cy3-conjugated anti-SMA, or rabbit anti-mouse PROX-1 antibodies.
Secondary antibodies were Alexa-conjugated (Molecular Probes). For
immunoperoxidase staining, tissues were incubated with biotinylated
goat anti-mouse VEGFR-3 antibody followed by Vectastain Elite
ABC reagent (Vector laboratories). Peroxidase activity was detected
with 3,30-diaminobenzidine (Sigma).
Cell Culture and Soft Agar Assays
MEFs of the three genetic backgrounds were isolated following stan-
dard protocol and maintained in DMEM supplemented with 10% fetal
bovine serum. Phoenix cells were used to generate ecotropic viruses.
MEFs were infected with filtered (pore size 0.45 mm) viral supernatant,
supplemented with 8 mg/ml polybrene. Primary MEFs were immortal-
ized by infecting with SV40 T antigen. Selected pools of immortalized
cells were infected with H-rasV12 pBABE puro or empty pBABE puro
as control. Twenty-four hours after infection, cells were selected with
1 mg/ml puromycin for at least 7 days. To monitor the capacity of MEFs
to grow in semi-solid medium in vitro, cells were transferred to 2 ml
complete DMEM containing 0.35% low-melting agarose. 13 103 cells
were seeded in duplicate into 60 mm dishes containing a 2 ml layer of
solidified 0.6% agar in complete medium. Colonies were stained 2
weeks later with Giemsa stain.
Supplemental Data
Supplemental Data include Experimental Procedures and five figures
and can be found with this article online at http://www.cell.com/cgi/
content/full/129/5/957/DC1/.
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